RE:RE:RE:RE:Management FailureThe PDUFA date is March 7, 2021 for FDA Approval of Aducanumab. It's not an extremely long wait but PMN might need a couple PPs by then. The only way they can increase SP value in the mean time is through the covid test with neutralizing antibodies identification success news and possible revenue in Q4 2020, which they talked about in the previous corporate update. However, it seems covid research is also progressing slower than I expected. They really need a catalyst to improve share price before doing a PP. I am beginning to wonder if it's the current large investors pushing the price down so they can load up heavily at a discounted price (with the assumption that aducanumab will be approved which will make PMN310 a huge success with big pharma partners).
G1945V wrote: "And if Aducanumab doesn't gain acceptance." then, in my opinion, the beta-amyloid hypothesis may very well end up dead in the water. PMN will have a much bigger hill to climb, sourcing badly needed funds to prove their
more targeted toxic form of amyloid-beta with PMN310.
I believe that Aducanumab will succeed, which will pave the way for PMN310 in a big way. jmo
G1945V